

Sept 5-8, 2023
Vidago Palace, Portugal
& Online

Sept 5, 2023 - Welcome Day (Porto, Portugal)

All Day Welcome day at FairJourney Biologics facilities
19h30 Cocktail and Welcome Dinner

Sept 6, 2023 - Keynote Cruise

7h00 - 7h45 Cruise Boarding
7h45 - 9h40 Cruise trip
Departure, Welcome Coffee and Networking

9h40 - 9h45 Welcome address - Day 1



Dennis Burton - Chairman The Antibody Series 2023
Professor at the Scripps Research Institute

Dennis Burton is the Chair and Professor in the Department of Immunology & Microbiology and holds the James & Jessie Minor Chair in Immunology. In 2022, in a list of Top Immunologists by Research.com, he placed 7th in the USA and 9th in the world. [Learn more](#)

Session 1 Keynote Talks

9h45 - 10h30 Design of antibody therapeutics with engineered specificity



Tomoyuki Igawa
Head of Translational Research Division, Chugai Pharmaceutical Co., Ltd. Japan

After serving as CEO and Research Head of Chugai Singapore, Dr. Igawa is currently the Head of Translational Research Division in Chugai Pharmaceutical, responsible for early clinical development. Dr. Igawa has published > 40 peer reviewed papers and is an inventor of > 90 patents in antibody drug discovery. [Learn more](#)

10h30 - 11h00 Coffee Break

11h00 - 11h45 Deconstructing polyclonal antibody responses at the molecular level using cryoEM



Andrew Ward
Professor at the Scripps Research Institute

Andrew Ward obtained a B.S. in Biology from Duke University in 2001. Upon graduation he moved to The Scripps Research Institute where he obtained his Ph.D. with Ronald Milligan, Ph.D. in cryoEM (2008) and conducted his postdoctoral work in structural biology and biophysics of membrane proteins with Geoffrey Chang, Ph.D. (2010). [Learn More](#)

11h45 - 12h00 Panel Discussion

12h00 - 14h00 Lunch and Chill-Out on the cruise

19h30 Barbecue Dinner at Vidago Palace
Partner Presentations

September 5 - 8

THE ANTIBODY SERIES 2023

BRINGING TOGETHER EXPERTS TO DISCUSS
INNOVATION IN ANTIBODY DISCOVERY AND
DEVELOPMENT

AGENDA

Learn more:



www.antibodyseries.com

Learn more at: www.antibodyseries.com

Sept 7, 2023 - Conference Day (Vidago Palace)

8h55 - 9h00

Welcome address - Day 2

Dennis Burton
Chairman

Session 2
Antibody Multivalency

9h00 - 9h30 Avidity engineering: a next frontier in the development of differentiating antibody therapeutics



Simone Oostindie

Director, Research and Discovery at Gyes B.V.

Dr. Simone Oostindie is Director, Research and Discovery at Gyes B.V., a biotechnology company that focuses on creating a pioneering Multispecific Antibody Platform (MAP) to discover and develop differentiated antibody therapeutics. [Learn more](#)

9h30 - 10h00 Three is a Magic Number: TAVO412 - A Novel Trispecific cMet x EGFR x VEGF Antibody for Difficult-to-Treat Cancers



Mark Chiu

Chief Scientific Officer at Tavotek Biotherapeutics

Dr. Chiu is the Chief Scientific Officer at Tavotek Biotherapeutics. He has nearly 35 years of experience in new drug discovery for AbbVie/Abbott Laboratories and Janssen. [Learn more](#)

10h00 - 10h15

Panel Discussion

10h15 - 11h00

Coffee Break & Partner Talk

10h15 - 10h30

High-throughput isolation and characterisation of monoclonal antibodies against PFRH5 – the leading blood-stage malaria vaccine candidate



Kirsty McHugh

PhD, Senior Postdoctoral Scientist PhD at University of Oxford

Kirsty completed her undergraduate degree in Molecular and Cellular Biochemistry followed by a DPhil in Clinical Medicine at the University of Oxford. Kirsty joined Simon Draper's group at the Jenner Institute in 2015 with research focus on the discovery, isolation and characterisation of monoclonal antibodies (mAb). Kirsty's research focus has since shifted to Malaria, where she is program lead for mAb discovery and analyses.



11h00 - 11h30 Tackling AIDS, COVID and Cancer with Multispecific Antibodies



Gary Nabel

Co-founder, President and CEO at ModeX Therapeutics

Dr. Gary Nabel co-founded ModeX Therapeutics and is President and CEO. Dr. Nabel was Chief Scientific Officer at Sanofi from 2012 to 2020 where he provided scientific oversight of Sanofi's research portfolio, guiding numerous projects into clinical development and eventual registration. During his tenure at Sanofi, he led the Breakthrough Laboratory where he developed the first trispecific antibody now in development for HIV. [Learn more](#)

11h30 - 12h00 Antibody Functional Screening Against Challenging Drug Targets



Brandon DeKosky

Associate Professor of Chemical Engineering, MIT and The Ragon Institute of MGH

Dr. Brandon DeKosky is an Associate Professor in the Department of Chemical Engineering at MIT and a Core Member of the Ragon Institute of MGH, Harvard, and MIT. Research efforts at the DeKosky lab have developed a suite of high-throughput single-cell platforms for large-scale analyses of adaptive immunity. [Learn more](#)

12h00 - 12h15

Panel Discussion

12h15 - 13h30

Lunch

Session 3
Antibodies, Computation and AI

13h30 - 14h00

Computational antibody profiling – from binding to developability design



Victor Greiff

Associate Professor for Systems Immunology at the University of Oslo

Victor Greiff is an Associate Professor for Systems Immunology at the University of Oslo since 2018. His group develops machine learning, computational and experimental tools for immune-repertoire-based in silico immunodiagnosics and immunotherapeutics discovery and design. He is the president of the Norwegian Society for Immunology and the current Chair of the AIRR Community. [Learn more](#)

14h00 - 14h30

AI-based tumor target and antibody discovery



X Shirley Liu

Co-founder and CEO of GV20 Therapeutics

Dr. X Shirley Liu is the co-founder and CEO of GV20 Therapeutics, a clinical stage immuno-oncology drug discovery company. Dr. Liu received PhD in Biomedical Informatics and PhD minor in Computer Science from Stanford University in 2002. Before joining GV20 in 2022, she has been a Professor of Biostatistics and Computational Biology at the Department of Data Science at Dana-Farber Cancer Institute (DFCI) and Harvard University. [Learn more](#)

14h30 - 15h00

A new era in (structural) biology - Impact of structure prediction using AI methods



Sameer Velankar

Head of Macromolecules, Structure, Chemistry and Bioimaging EMBL-EBI

Sameer Velankar leads the Protein Data Bank in Europe (PDBE) team at the EMBL-European Bioinformatics Institute. The team develops essential macromolecular structure resources and tools for biologists and other life scientists. [Learn more](#)

15h00 - 15h45

Coffee Break & Partner Presentation

15h15 - 15h30

Accelerating Antibody Development: Advancing Discovery through Integrated Bioinformatics and Machine Learning



Jannick Bendtsen

CEO of PipeBio



Jannick is co-founder and CEO of PipeBio, a leading bioinformatics platform catering to pharmaceutical and biotech companies engaged in antibody and therapeutic peptide research. Jannick holds a MSc in molecular biology and a PhD in bioinformatics and has an impressive scientific profile with more than 12,000 citations.

15h45 - 16h15

Mining the Immune System for Patient-Derived Protective Antibodies



Jane Osbourn

CSO at Alchemab Therapeutics Ltd

BSc in Biochemistry from University of Cambridge and PhD from John Innes Institute, Jane was awarded an OBE in 2019 for services to drug discovery and development. An early employee of CaT, Jane is currently CSO at Alchemab and Chair of Mogrify. [Learn more](#)

16h15 - 16h45

Improving computational models of human antibodies



Bryan Briney

Associate Professor Department of Immunology and Microbiology at the Scripps Research Institute

Dr. Briney is an Associate Professor in the department of Immunology and Microbiology at Scripps Research. He received his PhD from Vanderbilt University under the mentorship of James Crowe and trained as a postdoctoral fellow in Dennis Burton's laboratory at Scripps. [Learn more](#)

16h45 - 17h15

Panel Discussion

17h15 - 17h30

Closing Remarks

Dennis Burton
Chairman

20h00

Gala Dinner

Dress code: Black Tie

Sept 8, 2023 - Conference Day (Vidago Palace)

8h55 - 9h00

Welcome address - Day 3

Dennis Burton
Chairman

Session 4
Antibodies and Immunity

9h00 - 9h30 Sweetening your antibodies - lessons from natural immune responses



Gestur Vidarsson

Professor, PI and head of Immunoglobulin Research at Sanquin Research - Utrecht University

Prof. Dr. Vidarsson is a principal investigator at the Department of Experimental Immunohematology, head of Immunoglobulin Research laboratory at Sanquin Research and a professor of Immunoglobulin biopharmaceutics at the Department of Pharmaceutical Sciences at Utrecht University. [Learn more](#)

9h30 - 10h00 Investigation of T cell-antibody synergies in HIV/SIV immunotherapeutics



Louis Picker

Professor at Oregon Health & Science University

Dr. Louis J. Picker is the Associate Director of the Vaccine and Gene Therapy Institute, a Senior Scientist in the Pathobiology and Immunology Division of the Oregon National Primate Research Center, and a Professor of Pathology at the Oregon Health & Science University. [Learn more](#)

10h00 - 10h15

Panel Discussion

10h15 - 11h00

Coffee Break & Partner Presentation

10h15 - 10h30

Accelerating Antibody Development: Advancing Discovery through Integrated Bioinformatics and Machine Learning

ThermoFisher
SCIENTIFIC

Synthetic Biology tools to accelerate antibody development

Phillip Kuhn, Director R&D, Thermo Fisher Scientific

Phillip is R&D Director at Thermo Fisher Scientific / Geneart GmbH. With his passion for uniting biology, engineering and informatics, he has spearheaded many innovations to improve oligo and gene synthesis workflows and instrumentation, especially in miniaturized gene synthesis technologies.

Session 5
Novel Antibodies

11h00 - 11h30 The peculiar features of IgG4 MuSK antibodies and how they can be used as therapeutics



Maartje Huijbers

Associate Professor and Group Leader, Department of Human Genetics and Department of Neurology at LUMC

Dr. Maartje G. Huijbers is associate professor and group leader at the department of Human Genetics and the department of Neurology at LUMC in Leiden, The Netherlands. During her post doc she investigated the therapeutic potential of FcRn inhibition on MuSK myasthenia gravis and continued her work on neuromuscular autoimmune diseases at LUMC which escalated into the neuroimmunology group. [Learn more](#)

11h30 - 12h15

Efgartigimod, a novel FcRn antagonist for treatment of autoimmune diseases



Hans de Haard
Co-founder of Argenx

Hans de Haard is a serial pioneer of antibody platforms and has been active in the antibody engineering field since 1989. During his career, Prof. de Haard has discovered numerous therapeutic antibody leads, seven of which are now progressing in the clinic. [Learn more](#)

12h15 - 12h30

Panel Discussion

12h30 - 13h10

Novel Antibody Technologies for Future Therapeutics



Rene Hoet

Chief Innovations Officer at FairJourney Biologics

From April 2022, Prof. René Hoet is Chief Innovation Officer at FairJourney Biologics with the focus on implementation of new innovative antibody discovery and optimization technologies. He contributed to over 40 scientific papers and is inventor on 20 patent/patent applications. [Learn more](#)

13h10 - 13h25

Closing Remarks

Dennis Burton
Chairman

14h30

Departure to Porto w/ Lunch Box

Hosted and Organized by



Official Partners:

Platinum Partner:



Gold Partners:



Silver Partners:

